Equities research analysts expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings of ($1.40) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($1.45) and the highest estimate coming in at ($1.36). Atara Biotherapeutics reported earnings of ($1.29) per share during the same quarter last year, which would indicate a negative year over year growth rate of 8.5%. The business is expected to report its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Atara Biotherapeutics will report full year earnings of ($5.71) per share for the current fiscal year, with EPS estimates ranging from ($5.87) to ($5.51). For the next year, analysts anticipate that the business will report earnings of ($5.39) per share, with EPS estimates ranging from ($5.93) to ($4.83). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($1.45) by ($0.15).
A number of equities research analysts have commented on ATRA shares. Mizuho set a $43.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Citigroup set a $14.00 target price on shares of Atara Biotherapeutics and gave the stock a “hold” rating in a research report on Monday, August 12th. Cowen reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, September 13th. Stifel Nicolaus set a $36.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, Goldman Sachs Group cut shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $14.00 to $9.00 in a research note on Friday, September 27th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $29.75.
In other news, insider Joe Newell sold 3,500 shares of Atara Biotherapeutics stock in a transaction on Friday, September 27th. The shares were sold at an average price of $13.51, for a total transaction of $47,285.00. Following the transaction, the insider now owns 57,998 shares in the company, valued at approximately $783,552.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.00% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ATRA. Marshall Wace LLP purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at $284,000. Marshall Wace North America L.P. purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at $1,961,000. FMR LLC lifted its stake in shares of Atara Biotherapeutics by 21.7% during the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after buying an additional 1,143,787 shares in the last quarter. Coronation Fund Managers Ltd. lifted its stake in shares of Atara Biotherapeutics by 174.6% during the 2nd quarter. Coronation Fund Managers Ltd. now owns 92,050 shares of the biotechnology company’s stock valued at $1,851,000 after buying an additional 58,530 shares in the last quarter. Finally, Aperio Group LLC purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at $63,000. Institutional investors own 91.79% of the company’s stock.
NASDAQ:ATRA opened at $12.35 on Wednesday. The company has a current ratio of 7.80, a quick ratio of 7.80 and a debt-to-equity ratio of 0.06. Atara Biotherapeutics has a 12 month low of $11.50 and a 12 month high of $43.94. The company has a market cap of $663.67 million, a PE ratio of -2.34 and a beta of 2.09. The company has a 50 day simple moving average of $14.04 and a two-hundred day simple moving average of $20.75.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: Why is the LIBOR significant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.